SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.15 CNY | +1.31% |
|
+1.80% | +4.50% |
| Sales 2021 | 4.46B 616M | Sales 2022 | 5.09B 703M | Capitalization | 13.47B 1.86B |
|---|---|---|---|---|---|
| Net income 2021 | 705M 97.3M | Net income 2022 | 867M 120M | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 2.05B 283M | Net cash position 2022 | 3.41B 471M | EV / Sales 2022 | 1.97 x |
| P/E ratio 2021 |
13.6
x | P/E ratio 2022 |
15.7
x | Employees | 5,278 |
| Yield 2021 |
4.25% | Yield 2022 |
4.31% | Free-Float | 42.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.31% | ||
| 1 week | +1.80% | ||
| Current month | -0.98% | ||
| 1 month | +3.47% | ||
| 3 months | +13.74% | ||
| 6 months | +18.15% | ||
| Current year | +4.50% |
1 week
26.47
27.65
1 month
24.4127.85
Current year
21.5628.50
1 year
20.5430.32
3 years
12.8331.48
5 years
12.2931.48
10 years
10.9638.13
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Guan
CEO | Chief Executive Officer | 42 | 01-12-31 |
Chun Hong Wu
DFI | Director of Finance/CFO | 47 | - |
Fen Lan
CHM | Chairman | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Ling Guan
BRD | Director/Board Member | 64 | 14-03-25 |
Xian Wang Shi
BRD | Director/Board Member | 56 | 22-03-20 |
Jing Shang Ren
BRD | Director/Board Member | 62 | 11-04-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 4 M€ | -2.96% | ||
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 27.15 | +1.31% | 6,986,900 |
| 24-04-23 | 26.8 | -1.72% | 10,056,650 |
| 24-04-22 | 27.27 | +0.15% | 8,316,276 |
| 24-04-19 | 27.23 | +1.99% | 9,035,439 |
| 24-04-18 | 26.7 | +0.11% | 6,903,475 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.50% | 2.16B | |
| +17.97% | 42.77B | |
| +19.68% | 22.23B | |
| +13.12% | 14.44B | |
| +12.19% | 13.05B | |
| +35.45% | 11.59B | |
| -8.96% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 4.97B |
- Stock Market
- Equities
- 002737 Stock
